The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Venous Thrombosis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Venous Thrombosis


Psychiatry related information on Venous Thrombosis


High impact information on Venous Thrombosis


Chemical compound and disease context of Venous Thrombosis


Biological context of Venous Thrombosis


Anatomical context of Venous Thrombosis


Gene context of Venous Thrombosis


Analytical, diagnostic and therapeutic context of Venous Thrombosis


  1. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.P., Azarian, R., Laurent, M., Hirsch, J.L., Ferrari, E., Bosson, J.L., Mottier, D., Beau, B. N. Engl. J. Med. (1997) [Pubmed]
  2. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. Breddin, H.K., Hach-Wunderle, V., Nakov, R., Kakkar, V.V. N. Engl. J. Med. (2001) [Pubmed]
  3. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. den Heijer, M., Koster, T., Blom, H.J., Bos, G.M., Briet, E., Reitsma, P.H., Vandenbroucke, J.P., Rosendaal, F.R. N. Engl. J. Med. (1996) [Pubmed]
  4. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A.G., Demers, C., Kovacs, M. N. Engl. J. Med. (1996) [Pubmed]
  5. Heparin as an antithrombotic agent. Low-dose prophylaxis. Wessler, S. JAMA (1976) [Pubmed]
  6. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Pohl, C., Harbrecht, U., Greinacher, A., Theuerkauf, I., Biniek, R., Hanfland, P., Klockgether, T. Neurology (2000) [Pubmed]
  7. Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Leclerc, J.R., Geerts, W.H., Desjardins, L., Jobin, F., Laroche, F., Delorme, F., Haviernick, S., Atkinson, S., Bourgouin, J. Thromb. Haemost. (1992) [Pubmed]
  8. Heparin prophylaxis for deep venous thrombosis in a patient with multiple injuries: an evidence-based approach to a clinical problem. Hill, A.B., Garber, B., Dervin, G., Howard, A. Canadian journal of surgery. Journal canadien de chirurgie. (2002) [Pubmed]
  9. Homocysteine. The association with atherosclerotic vascular disease in older persons. Aronow, W.S. Geriatrics. (2003) [Pubmed]
  10. Low-molecular-weight heparin in patients with deep-vein thrombosis. Stricker, H., Mombelli, G. N. Engl. J. Med. (2001) [Pubmed]
  11. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G., Ageno, W. N. Engl. J. Med. (2001) [Pubmed]
  12. Images in clinical medicine. Cerebral venous thrombosis. Jaffer, A., Leifer, D. N. Engl. J. Med. (1997) [Pubmed]
  13. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. Bergqvist, D., Benoni, G., Björgell, O., Fredin, H., Hedlundh, U., Nicolas, S., Nilsson, P., Nylander, G. N. Engl. J. Med. (1996) [Pubmed]
  14. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis. Strandness, D.E. N. Engl. J. Med. (1996) [Pubmed]
  15. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. Hull, R., Raskob, G., Pineo, G., Rosenbloom, D., Evans, W., Mallory, T., Anquist, K., Smith, F., Hughes, G., Green, D. N. Engl. J. Med. (1993) [Pubmed]
  16. A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. Williams, J.J., Rodman, J.S., Peterson, C.M. N. Engl. J. Med. (1984) [Pubmed]
  17. Venous thrombosis results from some phenol injections. Macek, C. JAMA (1983) [Pubmed]
  18. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. Li, Y.D., Ye, B.Q., Zheng, S.X., Wang, J.T., Wang, J.G., Chen, M., Liu, J.G., Pei, X.H., Wang, L.J., Lin, Z.X., Gupta, K., Mackman, N., Slungaard, A., Key, N.S., Geng, J.G. J. Biol. Chem. (2009) [Pubmed]
  19. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Prandoni, P., Lensing, A.W., Büller, H.R., Carta, M., Cogo, A., Vigo, M., Casara, D., Ruol, A., ten Cate, J.W. Lancet (1992) [Pubmed]
  20. Plasma and urine beta-thromboglobulin concentration in patients with deep vein thrombosis. de Boer, A.C., Han, P., Turpie, A.G., Butt, R., Zielinsky, A., Genton, E. Blood (1981) [Pubmed]
  21. Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. Henke, P.K., DeBrunye, L.A., Strieter, R.M., Bromberg, J.S., Prince, M., Kadell, A.M., Sarkar, M., Londy, F., Wakefield, T.W. J. Immunol. (2000) [Pubmed]
  22. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Simonneau, G., Charbonnier, B., Decousus, H., Planchon, B., Ninet, J., Sie, P., Silsiguen, M., Combe, S. Arch. Intern. Med. (1993) [Pubmed]
  23. Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. Ireland, H.A., Boisclair, M.D., Taylor, J., Thompson, E., Thein, S.L., Girolami, A., De Caterina, M., Scopacasa, F., De Stefano, V., Leone, G., Finazzi, G., Cohen, H., Lane, D.A. Hum. Mutat. (1996) [Pubmed]
  24. Leiden factor V mutation in four patients with small bowel infarctions. Heresbach, D., Pagenault, M., Gueret, P., Crenn, P., Heresbach-Le Berre, N., Malledant, Y., Fauchet, R., Horellou, M.H., Silver, J., Messing, B., Bretagne, J.F. Gastroenterology (1997) [Pubmed]
  25. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Vanrenterghem, Y., Roels, L., Lerut, T., Gruwez, J., Michielsen, P., Gresele, P., Deckmyn, H., Colucci, M., Arnout, J., Vermylen, J. Lancet (1985) [Pubmed]
  26. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Biemond, B.J., Levi, M., Coronel, R., Janse, M.J., ten Cate, J.W., Pannekoek, H. Circulation (1995) [Pubmed]
  27. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Hong, A.P., Cook, D.J., Sigouin, C.S., Warkentin, T.E. Blood (2003) [Pubmed]
  28. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Eitzman, D.T., Westrick, R.J., Nabel, E.G., Ginsburg, D. Blood (2000) [Pubmed]
  29. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. Comp, P.C., Esmon, C.T. N. Engl. J. Med. (1984) [Pubmed]
  30. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Nguyen, G., Horellou, M.H., Kruithof, E.K., Conard, J., Samama, M.M. Blood (1988) [Pubmed]
  31. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Kluijtmans, L.A., Boers, G.H., Verbruggen, B., Trijbels, F.J., Novakova, I.R., Blom, H.J. Blood (1998) [Pubmed]
  32. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Declerck, P.J., Alessi, M.C., Verstreken, M., Kruithof, E.K., Juhan-Vague, I., Collen, D. Blood (1988) [Pubmed]
  33. Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Kunz, G., Ohlin, A.K., Adami, A., Zöller, B., Svensson, P., Lane, D.A. Blood (2002) [Pubmed]
  34. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Bezemer, I.D., Doggen, C.J., Vos, H.L., Rosendaal, F.R. Arch. Intern. Med. (2007) [Pubmed]
  35. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. Leyvraz, P.F., Richard, J., Bachmann, F., Van Melle, G., Treyvaud, J.M., Livio, J.J., Candardjis, G. N. Engl. J. Med. (1983) [Pubmed]
  36. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., McLoughlin, D., Armstrong, P. N. Engl. J. Med. (1979) [Pubmed]
  37. Diagnosis of deep-vein thrombosis: comparison of clinical evaluation, ultrasound, plethysmography, and venoscan with X-ray venogram. Sandler, D.A., Martin, J.F., Duncan, J.S., Blake, G.M., Ward, P., Ramsay, L.E., Lamont, A.C., Ross, B., Sherriff, S., Walton, L. Lancet (1984) [Pubmed]
  38. Changes in haemostatic system after application of a tourniquet. Klenerman, L., Chakrabarti, R., Mackie, I., Brozovic, M., Stirling, Y. Lancet (1977) [Pubmed]
  39. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. Kock, H.J., Schmit-Neuerburg, K.P., Hanke, J., Rudofsky, G., Hirche, H. Lancet (1995) [Pubmed]
WikiGenes - Universities